Proven for weeks and still live — safe to model.
Battle-tested: running 59 days across 1 GEO. Surviving this long usually means it's profitable enough to keep funding.
Running in a single market (United States) — a focused test, not a broad rollout yet.
- Seen 59/30 days
- 1 GEO
- Redirect chain checked
- LP host: thedoctorschannel.com
Reverse-engineered from the live ad — longevity, GEOs, and the affiliate funnel behind it. Verified by following the redirect chain on Jun 17. Free, no login.
Funnel, reverse-engineered
The campaign behind this creative
← the actual path the money takes.
Creative
The Doctor's Channel
Landing page
thedoctorschannel.com
where it lands
Product / Offer: not detected
Tracker: not detected
Affiliate network: not detected
How we know: the tracker and affiliate network come from the live redirect chain we followed and fingerprinted hop by hop. Greyed nodes weren’t detected.
Active
running 59d · last seen 1d ago · 1 market
Running with a modest observed footprint so far.
Gravity
—
push pressure now · 30d index
Strength
16/100
overall scale · 30d index
Run
59d
last seen 1d ago
Markets
1
countries seen
Landing page
thedoctorschannel.com
final host
Screenshot
—
not captured yet
Operator
—
unidentified
Network
Taboola
traffic source
Emerging AML Therapies 2025 – The Doctor's Channel
Top 10% longevity in network
Days alive is a profitability proxy — advertisers don’t pay to run losers.
Seen in
Geo reach
Single-geo testa single marketPredominantly Tier 1, concentrated in North America — United States.
What the data shows
The Doctor's Channel's Taboola creative has been running for 59 days across 1 country and first seen on April 19, 2026 and last seen on June 17, 2026. It has been observed in United States. The ad lands on thedoctorschannel.com. The Doctor's Channel is running 8 other creatives we have indexed, linked below for side-by-side comparison.
Creative headline: Emerging AML Therapies 2025 – The Doctor's Channel. Indexed on Taboola by mediabuyer.
Landing-page intelligence
Landing page intelligence
Where this ad lands
The lander is the product — screenshot, redirect chain, offer, tech stack, and on-page text in one place.
Landing page not captured yet
Our crawler renders each advertiser’s funnel on a rolling schedule. Recently observed ads are queued first — check back to see the full-page screenshot.
Host
thedoctorschannel.com
Path
/view/emerging-aml-therapies-2025/
Full URL
https://www.thedoctorschannel.com/view/emerging-aml-therapies-2025/
Redirect chain
Chain not captured yet.
Final host: thedoctorschannel.com. Hop-by-hop capture runs as a separate pipeline; ads observed in recent ingests get crawled first.
Tracking parameters
No query string on this URL.
Tracking setup · Taboola
Taboola passes site, site_id, campaign_id, campaign_item_id and click-id by default. Map those to your tracker's source/sub1-4 fields. Use {click_id} as your unique click identifier when posting back conversions.
?site={site}&site_id={site_id}&campaign_id={campaign_id}&campaign_item_id={campaign_item_id}&click-id={click_id}Default Taboola setup template: ?site={site}&site_id={site_id}&campaign_id={campaign_id}&campaign_item_id={campaign_item_id}&click-id={click_id}
Tech stack
No third-party monetization stack detected — this appears to be a direct landing page.
Landing page hubs
Landing page text
Show landing page text
Visible text extracted from the advertiser's landing page · last fetched 2026-06-17
▶
Landing page text
Show landing page text
Visible text extracted from the advertiser's landing page · last fetched 2026-06-17
Emerging AML Therapies 2025 – The Doctor's Channel Skip to main content Sign In Register Search Featured AML Content Hub Retinal Diseases Content Hub AAAAI 2026 Updates Content Hub Specialties Allergy / Immunology Cardiology Dermatology Melanoma Endocrinology Gastroenterology Ulcerative Colitis Indolent Systemic Mastocytosis Infectious Diseases Nephrology Kidney Disease Neurology Pompe Disease Ob/Gyn Oncology / Hematology CML Melanoma Metastatic Breast Cancer Multiple Myeloma NSCLC Renal Cell Carcinoma Thoracic Oncology Ophthalmology Retinal Diseases Pediatrics Preventative Health Primary Care Psychiatry Rheumatology Rheumatoid Arthritis The AML Content Hub Channel Emerging AML Therapies 2025 AML Content Hub Naval G. Daver, MD , a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, highlighted significant advancements in acute myeloid leukemia (AML) treatment, focusing on targeted therapies and combination regimens. He emphasized the role of FLT3 inhibitors, such as quizartinib and gilteritinib, in improving survival rates, particularly when combined with chemotherapy or venetoclax. Dr Daver also discussed the promising use of menin inhibitors like revumenib in treating KMT2A and NPM1-mutated AML, noting high response rates in relapsed/refractory cases. For IDH-mutated AML, triplet therapies combining azacitidine, venetoclax, and IDH inhibitors have shown impressive survival outcomes. Despite progress, he acknowledged the ongoing challenges in treating TP53-mutated AML and the need for innovative approaches, including immunotherapy and bispecific antibodies More Videos in AML Content Hub 26:41 Treatment Strategies for Therapy-Related and De Novo AML AML Clinical Content Hub In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases… 4:35 Considerations for Treatment Decision-Making in AML AML Content Hub David Sallman, MD, of @MoffittNews, discusses key considerations related to #treatmentselection in #AML. 2:12 Allogeneic Stem Cell Transplantation for Patients With Refractory AML AML Content Hub @Mohty_EBMT discusses long-term survival in patients with refractory #AML using allo-SCT at #EBMT21 3:56 The Impact of Genetics on Treatment for Patients With MDS AML Content Hub Valeria Santini, MD, University of Florence, Italy, discusses the #genomiclandscape of #MDS. ASH Releases Evidence-Based Guidelines for Treating Older Patients With AML AML Content Hub The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors… 1:33 Treating Secondary AML After HMAs AML Content Hub Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent… 2:56 Components of Risk Stratification in AML AML Content Hub An animation from #KnowAML provides a brief overview of risk stratification. 12:27 Evolving Role of Menin Inhibitors in AML AML Content Hub Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Eytan Stein, MD, Memorial… 1:34 SIERRA Trial Delivers Initial Data for Older Patients With AML AML Content Hub Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified… 1:11:42 AML Treatment Update AML Content Hub What are the latest treatment options for patients with #AML? @manosnikolousis discusses treatment options with a clinical nurse specialist and a patient with AML. 1:43 Considerations for the Management of IDH-Mutated AML AML Content Hub Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses practical considerations for treating patients with IDH-mutated acute myeloid leukemia. Dr Marvin-Peek highlights the… 5:38 Challenges Faced by Patients With AML in Complete Remission AML Content Hub At #EBMT2021, Norbert Vey, MD, of @paoli_calmettes, discusses #challenges faced by patients with #AML in #CompleteRemission. 56:57 New Horizons in AML Treatment AML Content Hub Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while… Christopher Hourigan, DM, DPhil, on Mutation-based MRD and Conditioning for AML AML Content Hub Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his… 23:03 Diagnostic Principles for TP53-Mutant AML AML Content Hub @JoeKhouryMD of @MDAndersonNews discusses #diagnosis of #AML with TP53 #mutations. :42 Tomivosertib Exhibits Potent Anti-leukemic Properties on AML Cells AML Content Hub Researchers from @LurieCancer and @nufeinbergmed present anti-leukemic properties of #tomivosertib as #therapy for #AML. 2:04 Genetic Testing Expands Therapeutic Treatment Options for Acute Myeloid Leukemia Patients AML Content Hub Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive… 2:14 Dr. Daver on the Utility of Maintenance Therapy in AML AML Content Hub Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy… 5:47 Combination Magrolimab and Azacitidine as a Frontline Therapy for TP53-Mutated Acute Myeloid Leukemia AML Content Hub Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and… 1:49 Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML AML Content Hub Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine… :58 Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials AML Content Hub Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for… 3:55 Targeted Therapy for Acute Myeloid Leukemia AML Content Hub Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park… 1:17 Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients AML Content Hub Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of… Round Two: Long Term Complications in Adolescent and Young Adult Acute Myeloid Leukemia Survivors AML Content Hub Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia… 25:27 Modern Approaches to AML Care AML Content Hub In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation… 1:35 Exploring the Data for AML Treated With Magrolimab and Azacitidine AML Content Hub Nava…
Text scraped from the landing page for research purposes. © respective owners. This text is sourced from the advertiser's public landing page; for removal, contact dmca@luba.media.
Observed daily (last 30 days)
No observations in this window.
Sibling creatives from this campaign
Other creatives in Other on Taboola
The rest of the set they’re running — see what else this angle is paired with.
Treating Secondary AML After HMAs – The Doctor's Channel
Comparison of consolidation strategies for pediatric patients with AML – The Doctor's Channel
Impact of Baseline Visual Acuity on Outcomes in DME – The Doctor's Channel
Wet Age-related Macular Degeneration (AMD) – Acute Presentation – The Doctor's Channel
Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria – The Doctor's Channel
Phase 2 Results: LP-003 Significantly Decreases Chronic Spontaneous Urticaria Disease Activity – The Doctor's Channel
Outcomes of High-Dose Aflibercept
Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration – The Doctor's Channel
Tested headline variants8
Tested headline variants
The Doctor's Channel's own A/B test — which headline they kept
The advertiser’s own A/B result, handed over: ranked by days running, the survivor on top. Variants they stopped running are struck through — they tested and killed those angles.
- #1Impact of Baseline Visual Acuity on Outcomes in DME – The Doctor's ChannelWinning angle60d8 content tokens
- #2Outcomes of High-Dose Aflibercept59d4 content tokens
- #3Treating Secondary AML After HMAs – The Doctor's Channel58d7 content tokens
- #4Wet Age-related Macular Degeneration (AMD) – Acute Presentation – The Doctor's Channel58d10 content tokens
Winning angle: the headline they kept alive longest — it beat the other variants they tested. Model this one; treat the rest as discarded experiments.
More from The Doctor's Channel8
More from The Doctor's Channel
Treating Secondary AML After HMAs – The Doctor's Channel Skip to main content…
thedoctorschannel.comMost spy tools stop at the creative. This page connects it to the campaign behind it — the funnel, the longevity, the GEOs. Free.